Challenges in the Treatment of Chronic Wounds

Robert G Frykberg, Jaminelli Banks, Robert G Frykberg, Jaminelli Banks

Abstract

Significance: Chronic wounds include, but are not limited, to diabetic foot ulcers, venous leg ulcers, and pressure ulcers. They are a challenge to wound care professionals and consume a great deal of healthcare resources around the globe. This review discusses the pathophysiology of complex chronic wounds and the means and modalities currently available to achieve healing in such patients. Recent Advances: Although often difficult to treat, an understanding of the underlying pathophysiology and specific attention toward managing these perturbations can often lead to successful healing. Critical Issues: Overcoming the factors that contribute to delayed healing are key components of a comprehensive approach to wound care and present the primary challenges to the treatment of chronic wounds. When wounds fail to achieve sufficient healing after 4 weeks of standard care, reassessment of underlying pathology and consideration of the need for advanced therapeutic agents should be undertaken. However, selection of an appropriate therapy is often not evidence based. Future Directions: Basic tenets of care need to be routinely followed, and a systematic evaluation of patients and their wounds will also facilitate appropriate care. Underlying pathologies, which result in the failure of these wounds to heal, differ among various types of chronic wounds. A better understanding of the differences between various types of chronic wounds at the molecular and cellular levels should improve our treatment approaches, leading to better healing rates, and facilitate the development of new more effective therapies. More evidence for the efficacy of current and future advanced wound therapies is required for their appropriate use.

Figures

https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4528992/bin/fig-5.jpg
Robert G. Frykberg, DPM, MPH
Figure 1.
Figure 1.
Molecular and cellular deficiencies in chronic wounds (red circles) and factors required to overcome them (green rectangles). Nonhealing ulcers and wounds represent a failure to achieve complete reepithelialization in the appropriate temporal sequence of tissue repair. Such wounds are characterized by excessive inflammation (including elevated levels of proteases, ROS, and inflammatory cytokines), by senescent cell populations with impaired proliferative and secretory capacities, and by defective MSCs. Excessive inflammation leads to degradation of newly synthesized growth factors and ECM. There is a need to restore the proper balance of cytokines, growth factors, and proteases, to recruit functional cells (epithelial cells, fibroblasts, and endothelial cells) to the wound area, and to deliver healthy functional MSCs directly to the wound to compensate for the patient's own dysfunctional stem cells. ECM, extracellular matrix; MSCs, mesenchymal stem cells; ROS, reactive oxygen species.
Figure 2.
Figure 2.
(A) Recurrent plantar ulcer not responsive to offloading. Biopsy revealed amelanotic melanoma. The clinician must be diligent in taking care to rule out the presence of malignancy in the wound either secondarily due to malignant degeneration as in the case of squamous cell carcinoma or as a primary lesion. (B) Cellulitis from infected digital wound with associated ischemia. Significant erythema can indicate cellulitis or infection requiring immediate hospitalization or might be an indicator of significant ischemia (dependent rubor). (C) Probe-to-bone test. If the bone is directly appreciated at the base of a wound, osteomyelitis is likely. A positive probe-to-bone test has a high predictive value for underlying osteomyelitis, even in the absence of acute signs of deep infection.
Figure 3.
Figure 3.
Simplified algorithm for diabetic foot ulcer (DFU) treatment.
Figure 4.
Figure 4.
Simplified algorithm for venous leg ulcer (VLU) treatment. ABI, ankle–brachial indices.

References

    1. Brownrigg JR, Apelqvist J, Bakker K, Schaper NC, Hinchliffe RJ. Evidence-based management of PAD & the diabetic foot. Eur J Vasc Endovasc Surg 2013;45:673–681
    1. Richmond NA, Maderal AD, Vivas AC. Evidence-based management of common chronic lower extremity ulcers. Dermatol Ther 2013;26:187–196
    1. Canadian Agency for Drugs and Technologies in Health. Optimal Care of Chronic, Non-Healing, Lower Extremity Wounds: A Review of Clinical Evidence and Guidelines. Ottawa, ON, Canada, 2013
    1. Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons NB. Burden of diabetic foot ulcers for medicare and private insurers. Diabetes Care 2014;37:651–658
    1. Shankaran V, Brooks M, Mostow E. Advanced therapies for chronic wounds: NPWT, engineered skin, growth factors, extracellular matrices. Dermatol Ther 2013;26:215–221
    1. Nunan R, Harding KG, Martin P. Clinical challenges of chronic wounds: searching for an optimal animal model to recapitulate their complexity. Dis Model Mech 2014;7:1205–1213
    1. Woo K, Ayello EA, Sibbald RG. The edge effect: current therapeutic options to advance the wound edge. Adv Skin Wound Care 2007;20:99–117; quiz 118–119
    1. Stojadinovic A, Carlson JW, Schultz GS, Davis TA, Elster EA. Topical advances in wound care. Gynecol Oncol 2008;111:S70–S80
    1. Attinger CE, Janis JE, Steinberg J, Schwartz J, Al-Attar A, Couch K. Clinical approach to wounds: debridement and wound bed preparation including the use of dressings and wound-healing adjuvants. Plast Reconstr Surg 2006;117:72S–109S
    1. Demidova-Rice TN, Salomatina EV, Yaroslavsky AN, Herman IM, Hamblin MR. Low-level light stimulates excisional wound healing in mice. Lasers Surg Med 2007;39:706–715
    1. Edmonds M. Body of knowledge around the diabetic foot and limb salvage. J Cardiovasc Surg (Torino) 2012;53:605–616
    1. Eming SA, Martin P, Tomic-Canic M. Wound repair and regeneration: mechanisms, signaling, and translation. Sci Transl Med 2014;6:265sr266
    1. Sun BK, Siprashvili Z, Khavari PA. Advances in skin grafting and treatment of cutaneous wounds. Science 2014;346:941–945
    1. Falanga V. Wound healing and its impairment in the diabetic foot. Lancet 2005;366:1736–1743
    1. Schultz GS, Sibbald RG, Falanga V, et al. . Wound bed preparation: a systematic approach to wound management. Wound Repair Regen 2003;11 Suppl 1:S1–S28
    1. McCarty SM, Percival SL. Proteases and delayed wound healing. Adv Wound Care 2013;2:438–447
    1. Schreml S, Szeimies RM, Prantl L, Karrer S, Landthaler M, Babilas P. Oxygen in acute and chronic wound healing. Br J Dermatol 2010;163:257–268
    1. Dhall S, Do DC, Garcia M, et al. . Generating and reversing chronic wounds in diabetic mice by manipulating wound redox parameters. J Diabetes Res 2014;2014:562625.
    1. Stanley A, Osler T. Senescence and the healing rates of venous ulcers. J Vasc Surg 2001;33:1206–1211
    1. Lobmann R, Ambrosch A, Schultz G, Waldmann K, Schiweck S, Lehnert H. Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients. Diabetologia 2002;45:1011–1016
    1. Tsourdi E, Barthel A, Rietzsch H, Reichel A, Bornstein SR. Current aspects in the pathophysiology and treatment of chronic wounds in diabetes mellitus. Biomed Res Int 2013;2013:385641.
    1. Bourguignon LY. Matrix hyaluronan-activated CD44 signaling promotes keratinocyte activities and improves abnormal epidermal functions. Am J Pathol 2014;184:1912–1919
    1. Cook H, Davies KJ, Harding KG, Thomas DW. Defective extracellular matrix reorganization by chronic wound fibroblasts is associated with alterations in TIMP-1, TIMP-2, and MMP-2 activity. J Invest Dermatol 2000;115:225–233
    1. Telgenhoff D, Shroot B. Cellular senescence mechanisms in chronic wound healing. Cell Death Differ 2005;12:695–698
    1. Wall IB, Moseley R, Baird DM, et al. . Fibroblast dysfunction is a key factor in the non-healing of chronic venous leg ulcers. J Invest Dermatol 2008;128:2526–2540
    1. Bitar MS. The GSK-3beta/Fyn/Nrf2 pathway in fibroblasts and wounds of type 2 diabetes: on the road to an evidence-based therapy of non-healing wounds. Adipocyte 2012;1:161–163
    1. Ennis WJ, Sui A, Bartholomew A. Stem cells and healing: impact on inflammation. Adv Wound Care 2013;2:369–378
    1. Cianfarani F, Toietta G, Di Rocco G, Cesareo E, Zambruno G, Odorisio T. Diabetes impairs adipose tissue-derived stem cell function and efficiency in promoting wound healing. Wound Repair Regen 2013;21:545–553
    1. Rodriguez-Menocal L, Salgado M, Ford D, Van Badiavas E. Stimulation of skin and wound fibroblast migration by mesenchymal stem cells derived from normal donors and chronic wound patients. Stem Cells Transl Med 2012;1:221–229
    1. Shin L, Peterson DA. Human mesenchymal stem cell grafts enhance normal and impaired wound healing by recruiting existing endogenous tissue stem/progenitor cells. Stem Cells Transl Med 2013;2:33–42
    1. Lazarus GS, Cooper DM, Knighton DR, et al. . Definitions and guidelines for assessment of wounds and evaluation of healing. Arch Dermatol 1994;130:489–493
    1. Chow O, Barbul A. Immunonutrition: role in wound healing and tissue regeneration. Adv Wound Care 2014;3:46–53
    1. Frykberg RG, Zgonis T, Armstrong DG, et al. . Diabetic foot disorders. A clinical practice guideline (2006 revision). J Foot Ankle Surg 2006;45:S1–S66
    1. Grayson ML, Gibbons GW, Balogh K, Levin E, Karchmer AW. Probing to bone in infected pedal ulcers. A clinical sign of underlying osteomyelitis in diabetic patients. JAMA 1995;273:721–723
    1. Alvaro-Afonso FJ, Lazaro-Martinez JL, Aragon-Sanchez J, Garcia-Morales E, Garcia-Alvarez Y, Molines-Barroso RJ. Inter-observer reproducibility of diagnosis of diabetic foot osteomyelitis based on a combination of probe-to-bone test and simple radiography. Diabetes Res Clin Pract 2014;105:e3–e5
    1. Abbott CA, Vileikyte L, Williamson S, Carrington AL, Boulton AJ. Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care 1998;21:1071–1075
    1. Young MJ, Breddy JL, Veves A, Boulton AJ. The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study. Diabetes Care 1994;17:557–560
    1. Boulton AJ, Kirsner RS, Vileikyte L. Clinical practice. Neuropathic diabetic foot ulcers. N Engl J Med 2004;351:48–55
    1. American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care 2003;26:3333–3341
    1. Boulton AJ, Armstrong DG, Albert SF, et al. . Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care 2008;31:1679–1685
    1. Gibbons GW, Wheelock FC, Jr., Siembieda C, Hoar CS, Jr., Rowbotham JL, Persson AB. Noninvasive prediction of amputation level in diabetic patients. Arch Surg 1979;114:1253–1257
    1. Kalani M, Brismar K, Fagrell B, Ostergren J, Jorneskog G. Transcutaneous oxygen tension and toe blood pressure as predictors for outcome of diabetic foot ulcers. Diabetes Care 1999;22:147–151
    1. Faglia E, Clerici G, Clerissi J, et al. . Long-term prognosis of diabetic patients with critical limb ischemia: a population-based cohort study. Diabetes Care 2009;32:822–827
    1. Faglia E, Clerici G, Clerissi J, et al. . When is a technically successful peripheral angioplasty effective in preventing above-the-ankle amputation in diabetic patients with critical limb ischaemia? Diabet Med 2007;24:823–829
    1. Conte MS. Challenges of distal bypass surgery in patients with diabetes: patient selection, techniques, and outcomes. J Am Podiatr Med Assoc 2010;100:429–438
    1. Chung J, Modrall JG, Ahn C, Lavery LA, Valentine RJ. Multidisciplinary care improves amputation-free survival in patients with chronic critical limb ischemia. J Vasc Surg 2015;61:162–169e161
    1. Collins L, Seraj S. Diagnosis and treatment of venous ulcers. Am Fam Physician 2010;81:989–996
    1. Brem H, Kirsner RS, Falanga V. Protocol for the successful treatment of venous ulcers. Am J Surg 2004;188:1–8
    1. O'Donnell TF, Jr., Passman MA, Marston WA, et al. . Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery (R) and the American Venous Forum. J Vasc Surg 2014;60:3S–59S
    1. Lipsky BA, Berendt AR, Cornia PB, et al. . 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2012;54:e132–e173
    1. Pineda C, Espinosa R, Pena A. Radiographic imaging in osteomyelitis: the role of plain radiography, computed tomography, ultrasonography, magnetic resonance imaging, and scintigraphy. Semin Plast Surg 2009;23:80–89
    1. Wagner FW., Jr. The dysvascular foot: a system for diagnosis and treatment. Foot Ankle 1981;2:64–122
    1. Armstrong DG, Lavery LA, Harkless LB. Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care 1998;21:855–859
    1. Schaper NC. Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. Diabetes Metab Res Rev 2004;20 Suppl 1:S90–S95
    1. Eklof B, Rutherford RB, Bergan JJ, et al. . Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg 2004;40:1248–1252
    1. National Pressure Ulcer Advisory Panel, European Pressure Ulcer Advisory Panel, Pan Pacific Pressure Injury Alliance. Prevention and Treatment of Pressure Ulcers: Quick Reference Guide. Perth, Australia: Cambridge Media, 2014.
    1. Oyibo SO, Jude EB, Tarawneh I, Nguyen HC, Harkless LB, Boulton AJ. A comparison of two diabetic foot ulcer classification systems: the Wagner and the University of Texas wound classification systems. Diabetes Care 2001;24:84–88
    1. Kaiser M, Yafi A, Cinat M, Choi B, Durkin AJ. Noninvasive assessment of burn wound severity using optical technology: a review of current and future modalities. Burns 2011;37:377–386
    1. Khan F, Newton DJ. Laser Doppler imaging in the investigation of lower limb wounds. Int J Low Extrem Wounds 2003;2:74–86
    1. Kuck M, Strese H, Alawi SA, et al. . Evaluation of optical coherence tomography as a non-invasive diagnostic tool in cutaneous wound healing. Skin Res Technol 2014;20:1–7
    1. Xu RX, Huang K, Qin R, et al. . Dual-mode imaging of cutaneous tissue oxygenation and vascular function. J Vis Exp 2010:2095.
    1. Yudovsky D, Nouvong A, Pilon L. Hyperspectral imaging in diabetic foot wound care. J Diabetes Sci Technol 2010;4:1099–1113
    1. Apelqvist J, Bakker K, van Houtum WH, Schaper NC, International Working Group on the Diabetic Foot Editorial B. Practical guidelines on the management and prevention of the diabetic foot: based upon the International Consensus on the Diabetic Foot (2007) Prepared by the International Working Group on the Diabetic Foot. Diabetes Metab Res Rev 2008;24 Suppl 1:S181–S187
    1. Snyder RJ, Kirsner RS, Warriner RA, 3rd, Lavery LA, Hanft JR, Sheehan P. Consensus recommendations on advancing the standard of care for treating neuropathic foot ulcers in patients with diabetes. Ostomy Wound Manage 2010;56:S1–S24
    1. Molnar JA, Underdown MJ, Clark WA. Nutrition and chronic wounds. Adv Wound Care 2014;3:663–681
    1. Patel GK. The role of nutrition in the management of lower extremity wounds. Int J Low Extrem Wounds 2005;4:12–22
    1. Bradbury AW, Adam DJ, Bell J, et al. . Multicentre randomised controlled trial of the clinical and cost-effectiveness of a bypass-surgery-first versus a balloon-angioplasty-first revascularisation strategy for severe limb ischaemia due to infrainguinal disease. The Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial. Health Technol Assess 2010;14:1–210, iii–iv
    1. Mills JL, Sr., Conte MS, Armstrong DG, et al. . The Society for Vascular Surgery Lower Extremity Threatened Limb Classification System: risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg 2014;59:220–234.e221–e222
    1. Londahl M, Katzman P, Nilsson A, Hammarlund C. Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes. Diabetes Care 2010;33:998–1003
    1. Kranke P, Bennett M, Roeckl-Wiedmann I, Debus S. Hyperbaric oxygen therapy for chronic wounds. Cochrane Database Syst Rev 2004;4:CD004123
    1. Leslie CA, Sapico FL, Ginunas VJ, Adkins RH. Randomized controlled trial of topical hyperbaric oxygen for treatment of diabetic foot ulcers. Diabetes Care 1988;11:111–115
    1. Gordillo GM, Sen CK. Evidence-based recommendations for the use of topical oxygen therapy in the treatment of lower extremity wounds. Int J Low Extrem Wounds 2009;8:105–111
    1. Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care 1990;13:513–521
    1. Faglia E, Clerici G, Caminiti M, Quarantiello A, Gino M, Morabito A. The role of early surgical debridement and revascularization in patients with diabetes and deep foot space abscess: retrospective review of 106 patients with diabetes. J Foot Ankle Surg 2006;45:220–226
    1. Panuncialman J, Falanga V. The science of wound bed preparation. Clin Plast Surg 2007;34:621–632
    1. Lazaro-Martinez JL, Aragon-Sanchez J, Garcia-Morales E. Antibiotics versus conservative surgery for treating diabetic foot osteomyelitis: a randomized comparative trial. Diabetes Care 2014;37:789–795
    1. Granick M, Boykin J, Gamelli R, Schultz G, Tenenhaus M. Toward a common language: surgical wound bed preparation and debridement. Wound Repair Regen 2006;14 Suppl 1:S1–S10
    1. Leaper DJ, Schultz G, Carville K, Fletcher J, Swanson T, Drake R. Extending the TIME concept: what have we learned in the past 10 years?. Int Wound J 2012;9 Suppl 2:1–19
    1. Ligresti C, Bo F. Wound bed preparation of difficult wounds: an evolution of the principles of TIME. Int Wound J 2007;4:21–29
    1. Schultz G, Mozingo D, Romanelli M, Claxton K. Wound healing and TIME; new concepts and scientific applications. Wound Repair Regen 2005;13:S1–S11
    1. Cardinal M, Eisenbud DE, Armstrong DG, et al. . Serial surgical debridement: a retrospective study on clinical outcomes in chronic lower extremity wounds. Wound Repair Regen 2009;17:306–311
    1. Steed DL, Donohoe D, Webster MW, Lindsley L. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. Diabetic Ulcer Study Group. J Am Coll Surg 1996;183:61–64
    1. Piaggesi A, Schipani E, Campi F, et al. . Conservative surgical approach versus non-surgical management for diabetic neuropathic foot ulcers: a randomized trial. Diabet Med 1998;15:412–417
    1. Falanga V, Brem H, Ennis WJ, Wolcott R, Gould LJ, Ayello EA. Maintenance debridement in the treatment of difficult-to-heal chronic wounds. Recommendations of an expert panel. Ostomy Wound Manage 2008;Suppl:2–13; quiz 14–15
    1. Sherman RA. Maggot versus conservative debridement therapy for the treatment of pressure ulcers. Wound Repair Regen 2002;10:208–214
    1. Tian X, Liang XM, Song GM, Zhao Y, Yang XL. Maggot debridement therapy for the treatment of diabetic foot ulcers: a meta-analysis. J Wound Care 2013;22:462–469
    1. Steed DL, Attinger C, Colaizzi T, et al. . Guidelines for the treatment of diabetic ulcers. Wound Repair Regen 2006;14:680–692
    1. Brem H, Tomic-Canic M. Cellular and molecular basis of wound healing in diabetes. J Clin Invest 2007;117:1219–1222
    1. Snyder RJ, Frykberg RG, Rogers LC, et al. . The management of diabetic foot ulcers through optimal off-loading building consensus guidelines and practical recommendations to improve outcomes. J Am Podiatr Med Assoc 2014;104:555–567
    1. Armstrong DG, Nguyen HC, Lavery LA, van Schie CH, Boulton AJ, Harkless LB. Off-loading the diabetic foot wound: a randomized clinical trial. Diabetes Care 2001;24:1019–1022
    1. Cavanagh PR, Bus SA. Off-loading the diabetic foot for ulcer prevention and healing. J Am Podiatr Med Assoc 2010;100:360–368
    1. Lewis J, Lipp A. Pressure-relieving interventions for treating diabetic foot ulcers. Cochrane Database Syst Rev 2013;1:CD002302
    1. Katz IA, Harlan A, Miranda-Palma B, et al. . A randomized trial of two irremovable off-loading devices in the management of plantar neuropathic diabetic foot ulcers. Diabetes Care 2005;28:555–559
    1. Dolibog P, Franek A, Taradaj J, et al. . A randomized, controlled clinical pilot study comparing three types of compression therapy to treat venous leg ulcers in patients with superficial and/or segmental deep venous reflux. Ostomy Wound Manage 2013;59:22–30
    1. Kimmel H, Robin A. An evidence-based algorithm for treating venous leg ulcers utilizing the cochrane database of systematic reviews. Wounds 2013;25:242–250
    1. Frykberg RG, Bevilacqua NJ, Habershaw G. Surgical off-loading of the diabetic foot. J Vasc Surg 2010;52:44S–58S
    1. Armstrong DG, Frykberg RG. Classifying diabetic foot surgery: toward a rational definition. Diabet Med 2003;20:329–331
    1. La Fontaine J, Lavery LA, Hunt NA, Murdoch DP. The role of surgical off-loading to prevent recurrent ulcerations. Int J Low Extrem Wounds 2014;13:320–334
    1. Armstrong DG, Lavery LA, Stern S, Harkless LB. Is prophylactic diabetic foot surgery dangerous? J Foot Ankle Surg 1996;35:585–589
    1. Belczyk RJ, Rogers LC, Andros G, Wukich DK, Burns PR. External fixation techniques for plastic and reconstructive surgery of the diabetic foot. Clin Podiatr Med Surg 2011;28:649–660
    1. Blume PA, Donegan R, Schmidt BM. The role of plastic surgery for soft tissue coverage of the diabetic foot and ankle. Clin Podiatr Med Surg 2014;31:127–150
    1. Sayner LR, Rosenblum BI, Giurini JM. Elective surgery of the diabetic foot. Clin Podiatr Med Surg 2003;20:783–792
    1. Laborde JM. Treatment of diabetic foot ulcers with tendon lengthening. Am Fam Physician 2009;80:1351; author reply 1351
    1. Lin SS, Lee TH, Wapner KL. Plantar forefoot ulceration with equinus deformity of the ankle in diabetic patients: the effect of tendo-Achilles lengthening and total contact casting. Orthopedics 1996;19:465–475
    1. Armstrong DG, Lavery LA, Frykberg RG, Wu SC, Boulton AJ. Validation of a diabetic foot surgery classification. Int Wound J 2006;3:240–246
    1. Piaggesi A, Goretti C, Mazzurco S, et al. . A randomized controlled trial to examine the efficacy and safety of a new super-oxidized solution for the management of wide postsurgical lesions of the diabetic foot. Int J Low Extrem Wounds 2010;9:10–15
    1. Carter MJ, Tingley-Kelley K, Warriner RA., 3rd Silver treatments and silver-impregnated dressings for the healing of leg wounds and ulcers: a systematic review and meta-analysis. J Am Acad Dermatol 2010;63:668–679
    1. Chambers H, Dumville JC, Cullum N. Silver treatments for leg ulcers: a systematic review. Wound Repair Regen 2007;15:165–173
    1. Bakker K, Apelqvist J, Schaper NC. Practical guidelines on the management and prevention of the diabetic foot 2011. Diabetes Metab Res Rev 2012;28 Suppl 1:225–231
    1. American Diabetes Association. Consensus development conference on diabetic foot wound care. Diabetes Care 1999;22:1354.
    1. Sheehan P, Jones P, Caselli A, Giurini JM, Veves A. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care 2003;26:1879–1882
    1. Veves A, Sheehan P, Pham HT. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg 2002;137:822–827
    1. Cardinal M, Eisenbud DE, Phillips T, Harding K. Early healing rates and wound area measurements are reliable predictors of later complete wound closure. Wound Repair Regen 2008;16:19–22
    1. Boulton AJ. The diabetic foot: from art to science. The 18th Camillo Golgi lecture. Diabetologia 2004;47:1343–1353
    1. Snyder RJ, Cardinal M, Dauphinee DM, Stavosky J. A post-hoc analysis of reduction in diabetic foot ulcer size at 4 weeks as a predictor of healing by 12 weeks. Ostomy Wound Manage 2010;56:44–50
    1. Mulder G, Tenenhaus M, D'Souza GF. Reduction of diabetic foot ulcer healing times through use of advanced treatment modalities. Int J Low Extrem Wounds 2014;13:335–346
    1. Kirsner RS, Warriner R, Michela M, Stasik L, Freeman K. Advanced biological therapies for diabetic foot ulcers. Arch Dermatol 2010;146:857–862
    1. Wu SC, Marston W, Armstrong DG. Wound care: the role of advanced wound healing technologies. J Vasc Surg 2010;52:59S–66S
    1. Armstrong DG, Boulton AJ, Banwell P. Negative pressure wound therapy in treatment of diabetic foot wounds: a marriage of modalities. Ostomy Wound Manage 2004;50:9–12
    1. Banwell PE. Topical negative pressure therapy in wound care. J Wound Care 1999;8:79–84
    1. Morykwas MJ, Simpson J, Punger K, Argenta A, Kremers L, Argenta J. Vacuum-assisted closure: state of basic research and physiologic foundation. Plast Reconstr Surg 2006;117:121S–126S
    1. Petrie N, Potter M, Banwell P. The management of lower extremity wounds using topical negative pressure. Int J Low Extrem Wounds 2003;2:198–206
    1. Smith APS, Whittington K, Frykberg RG, DeLeon J. Negative pressure wound therapy. In: Krasner DL, Rodeheaver GT, Sibbald RG, Woo KY, eds. Chronic Wound Care 5: A Clinical Source Book for Healthcare Professionals. Malvern, PA: HMP Communications, 2012:271–299
    1. Argenta LC, Morykwas MJ. Vacuum-assisted closure: a new method for wound control and treatment: clinical experience. Ann Plast Surg 1997;38:563–576; discussion 577
    1. Morykwas MJ, Argenta LC, Shelton-Brown EI, McGuirt W. Vacuum-assisted closure: a new method for wound control and treatment: animal studies and basic foundation. Ann Plast Surg 1997;38:553–562
    1. Andros G, Armstrong DG, Attinger CE, et al. . Consensus statement on negative pressure wound therapy (V.A.C. Therapy) for the management of diabetic foot wounds. Ostomy Wound Manage 2006;Suppl:1–32
    1. Isaac AL, Armstrong DG. Negative pressure wound therapy and other new therapies for diabetic foot ulceration: the current state of play. Med Clin North Am 2013;97:899–909
    1. Dalla Paola L. Diabetic foot wounds: the value of negative pressure wound therapy with instillation. Int Wound J 2013;10 Suppl 1:25–31
    1. Ubbink DT, Westerbos SJ, Evans D, Land L, Vermeulen H. Topical negative pressure for treating chronic wounds. Cochrane Database Syst Rev 2008:CD001898.
    1. Armstrong DG, Lavery LA. Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial. Lancet 2005;366:1704–1710
    1. Blume PA, Walters J, Payne W, Ayala J, Lantis J. Comparison of negative pressure wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial. Diabetes Care 2008;31:631–636
    1. Ubbink DT, Westerbos SJ, Nelson EA, Vermeulen H. A systematic review of topical negative pressure therapy for acute and chronic wounds. Br J Surg 2008;95:685–692
    1. Saxena V, Hwang CW, Huang S, Eichbaum Q, Ingber D, Orgill DP. Vacuum-assisted closure: microdeformations of wounds and cell proliferation. Plast Reconstr Surg 2004;114:1086–1096; discussion 1097–1088
    1. Scherer SS, Pietramaggiori G, Mathews JC, Prsa MJ, Huang S, Orgill DP. The mechanism of action of the vacuum-assisted closure device. Plast Reconstr Surg 2008;122:786–797
    1. Isaac AL, Rose J, Armstrong DG. Mechanically powered negative pressure wound therapy as a bolster for skin grafting. Plast Reconstr Surg Glob Open 2014;2:e103.
    1. Bollero D, Degano K, Gangemi EN, Aloj D, Malvasio V, Stella M. Long-term follow-up of negative pressure wound therapy with instillation: a limb salvage procedure? Int Wound J 2014. [Epub ahead of print]; DOI: 10.1111/iwj.12373
    1. Kim PJ, Attinger CE, Steinberg JS, et al. . The impact of negative-pressure wound therapy with instillation compared with standard negative-pressure wound therapy: a retrospective, historical, cohort, controlled study. Plast Reconstr Surg 2014;133:709–716
    1. Wolvos TA. Negative pressure wound therapy with instillation: the current state of the art. Surg Technol Int 2014;24:53–62
    1. Fong KD, Marston WA. SNaP wound care system: ultraportable mechanically powered negative pressure wound therapy. Adv Wound Care 2012;1:41–43
    1. Bohn G. Mechanically powered ambulatory negative pressure wound therapy device for treatment of a colostomy takedown site. J Wound Ostomy Continence Nurs 2013;40:315–317
    1. Armstrong DG, Marston WA, Reyzelman AM, Kirsner RS. Comparative effectiveness of mechanically and electrically powered negative pressure wound therapy devices: a multicenter randomized controlled trial. Wound Repair Regen 2012;20:332–341
    1. Armstrong DG, Marston WA, Reyzelman AM, Kirsner RS. Comparison of negative pressure wound therapy with an ultraportable mechanically powered device vs. traditional electrically powered device for the treatment of chronic lower extremity ulcers: a multicenter randomized-controlled trial. Wound Repair Regen 2011;19:173–180
    1. Neiderer K, Martin B, Hoffman S, Jolley D, Dancho J. A mechanically powered negative pressure device used in conjunction with a bioengineered cell-based product for the treatment of pyoderma gangrenosum: a case report. Ostomy Wound Manage 2012;58:44–48
    1. Fife CE, Buyukcakir C, Otto G, Sheffield P, Love T, Warriner R., 3rd Factors influencing the outcome of lower-extremity diabetic ulcers treated with hyperbaric oxygen therapy. Wound Repair Regen 2007;15:322–331
    1. Fife CE, Hopf H. Discussion. Hyperbaric oxygen: its mechanisms and efficacy. Plast Reconstr Surg 2011;127 Suppl 1:142S–143S
    1. Londahl M. Hyperbaric oxygen therapy as adjunctive treatment for diabetic foot ulcers. Int J Low Extrem Wounds 2013;12:152–157
    1. Roeckl-Wiedmann I, Bennett M, Kranke P. Systematic review of hyperbaric oxygen in the management of chronic wounds. Br J Surg 2005;92:24–32
    1. Stoekenbroek RM, Santema TB, Legemate DA, Ubbink DT, van den Brink A, Koelemay MJ. Hyperbaric oxygen for the treatment of diabetic foot ulcers: a systematic review. Eur J Vasc Endovasc Surg 2014;47:647–655
    1. Wunderlich RP, Peters EJ, Lavery LA. Systemic hyperbaric oxygen therapy: lower-extremity wound healing and the diabetic foot. Diabetes Care 2000;23:1551–1555
    1. Zamboni WA, Browder LK, Martinez J. Hyperbaric oxygen and wound healing. Clin Plast Surg 2003;30:67–75
    1. Abidia A, Laden G, Kuhan G, et al. . The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomised-controlled trial. Eur J Vasc Endovasc Surg 2003;25:513–518
    1. Baroni G, Porro T, Faglia E, et al. . Hyperbaric oxygen in diabetic gangrene treatment. Diabetes Care 1987;10:81–86
    1. Faglia E, Favales F, Aldeghi A, et al. . Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer. A randomized study. Diabetes Care 1996;19:1338–1343
    1. Hammarlund C, Sundberg T. Hyperbaric oxygen reduced size of chronic leg ulcers: a randomized double-blind study. Plast Reconstr Surg 1994;93:829–833; discussion 834
    1. Kessler L, Bilbault P, Ortega F, et al. . Hyperbaric oxygenation accelerates the healing rate of nonischemic chronic diabetic foot ulcers: a prospective randomized study. Diabetes Care 2003;26:2378–2382
    1. Zamboni WA, Wong HP, Stephenson LL, Pfeifer MA. Evaluation of hyperbaric oxygen for diabetic wounds: a prospective study. Undersea Hyperb Med 1997;24:175–179
    1. Kranke P, Bennett MH, Martyn-St James M, Schnabel A, Debus SE. Hyperbaric oxygen therapy for chronic wounds. Cochrane Database Syst Rev 2012;4:CD004123
    1. Margolis DJ, Gupta J, Hoffstad O, et al. . Lack of effectiveness of hyperbaric oxygen therapy for the treatment of diabetic foot ulcer and the prevention of amputation: a cohort study. Diabetes Care 2013;36:1961–1966
    1. Sen CK. Wound healing essentials: let there be oxygen. Wound Repair Regen 2009;17:1–18
    1. Tawfick WA, Sultan S. Technical and clinical outcome of topical wound oxygen in comparison to conventional compression dressings in the management of refractory nonhealing venous ulcers. Vasc Endovascular Surg 2013;47:30–37
    1. Fries RB, Wallace WA, Roy S, et al. . Dermal excisional wound healing in pigs following treatment with topically applied pure oxygen. Mutat Res 2005;579:172–181
    1. Blackman E, Moore C, Hyatt J, Railton R, Frye C. Topical wound oxygen therapy in the treatment of severe diabetic foot ulcers: a prospective controlled study. Ostomy Wound Manage 2010;56:24–31
    1. Gordillo GM, Roy S, Khanna S, et al. . Topical oxygen therapy induces vascular endothelial growth factor expression and improves closure of clinically presented chronic wounds. Clin Exp Pharmacol Physiol 2008;35:957–964
    1. Gordillo GM, Schlanger R, Wallace WA, Bergdall V, Bartlett R, Sen CK. Protocols for topical and systemic oxygen treatments in wound healing. Methods Enzymol 2004;381:575–585
    1. Kalliainen LK, Gordillo GM, Schlanger R, Sen CK. Topical oxygen as an adjunct to wound healing: a clinical case series. Pathophysiology 2003;9:81–87
    1. Orsted HL, Poulson R, Advisory G, et al. . Evidence-based practice standards for the use of topical pressurised oxygen therapy. Int Wound J 2012;9:271–284
    1. Said HK, Hijjawi J, Roy N, Mogford J, Mustoe T. Transdermal sustained-delivery oxygen improves epithelial healing in a rabbit ear wound model. Arch Surg 2005;140:998–1004
    1. Tawfick W, Sultan S. Does topical wound oxygen (TWO2) offer an improved outcome over conventional compression dressings (CCD) in the management of refractory venous ulcers (RVU)? A parallel observational comparative study. Eur J Vasc Endovasc Surg 2009;38:125–132
    1. Woo KY, Coutts PM, Sibbald RG. Continuous topical oxygen for the treatment of chronic wounds: a pilot study. Adv Skin Wound Care 2012;25:543–547
    1. Ennis WJ, Lee C, Plummer M, Meneses P. Current status of the use of modalities in wound care: electrical stimulation and ultrasound therapy. Plast Reconstr Surg 2011;127 Suppl 1:93S–102S
    1. Graebert JK, Henzel MK, Honda KS, Bogie KM. Systemic evaluation of electrical stimulation for ischemic wound therapy in a preclinical model. Adv Wound Care 2014;3:428–437
    1. Kloth LC. Electrical stimulation technologies for wound healing. Adv Wound Care 2014;3:81–90
    1. Houghton PE, Campbell KE. Therapeutic modalities in the treatment of chronic recalcitrant wounds. In: Krasner DL, Rodeheaver GT, Sibbald RG, Woo KY, eds. Chronic Wound Care 5: A Clinical Source Book for Healthcare Professionals. Malvern, PA: HMP Communications, 2012:253–270
    1. Baker LL, Chambers R, DeMuth SK, Villar F. Effects of electrical stimulation on wound healing in patients with diabetic ulcers. Diabetes Care 1997;20:405–412
    1. Kloth LC. Electrical stimulation for wound healing: a review of evidence from in vitro studies, animal experiments, and clinical trials. Int J Low Extrem Wounds 2005;4:23–44
    1. McCulloch J. Electrical stimulation in wound repair. In: Yee BY, ed. The Wound Management Manual. New York, NY: McGraw Hill, 2005:80–89
    1. Fernandez-Chimeno M, Houghton PE, Holey L. Electrical stimulation for chronic wounds (Protocol). Cochrane Database Syst Rev 2004:CD004550
    1. Frykberg R, Tierney E, Tallis A, Klotzbach T. Cell proliferation induction: healing chronic wounds through low-energy pulsed radiofrequency. Int J Low Extrem Wounds 2009;8:45–51
    1. Frykberg RG, Driver VR, Lavery LA, Armstrong DG, Isenberg RA. The use of pulsed radio frequency energy therapy in treating lower extremity wounds: results of a retrospective study of a wound registry. Ostomy Wound Manage 2011;57:22–29
    1. Moffett J, Griffin NE, Ritz MC, George FR. Pulsed radio frequency energy field treatment of cells in culture results in increased expression of genes involved in the inflammation phase of lower extremity diabetic wound healing. J Diabet Foot Complications 2010;2:57–64
    1. Wendelken ME, Markowitz L, Alvarez OM. A closer look at ultrasonic debridement. Podiatry Today 2010;23:23–28
    1. Amini S, Shojaeefard A, Annabestani Z, et al. . Low-frequency ultrasound debridement in patients with diabetic foot ulcers and osteomyelitis. Wounds 2013;25:193–198
    1. Stanisic MM, Provo BJ, Larson DL, Kloth LC. Wound debridement with 25 kHz ultrasound. Adv Skin Wound Care 2005;18:484–490
    1. Ennis WJ, Foremann P, Mozen N, Massey J, Conner-Kerr T, Meneses P. Ultrasound therapy for recalcitrant diabetic foot ulcers: results of a randomized, double-blind, controlled, multicenter study. Ostomy Wound Manage 2005;51:24–39
    1. Ennis WJ, Valdes W, Gainer M, Meneses P. Evaluation of clinical effectiveness of MIST ultrasound therapy for the healing of chronic wounds. Adv Skin Wound Care 2006;19:437–446
    1. Kavros SJ, Liedl DA, Boon AJ, Miller JL, Hobbs JA, Andrews KL. Expedited wound healing with noncontact, low-frequency ultrasound therapy in chronic wounds: a retrospective analysis. Adv Skin Wound Care 2008;21:416–423
    1. Kavros SJ, Miller JL, Hanna SW. Treatment of ischemic wounds with noncontact, low-frequency ultrasound: the Mayo clinic experience, 2004–2006. Adv Skin Wound Care 2007;20:221–226
    1. Kavros SJ, Schenck EC. Use of noncontact low-frequency ultrasound in the treatment of chronic foot and leg ulcerations: a 51-patient analysis. J Am Podiatr Med Assoc 2007;97:95–101
    1. Dymarek R, Halski T, Ptaszkowski K, Slupska L, Rosinczuk J, Taradaj J. Extracorporeal shock wave therapy as an adjunct wound treatment: a systematic review of the literature. Ostomy Wound Manage 2014;60:26–39
    1. Mittermayr R, Antonic V, Hartinger J, et al. . Extracorporeal shock wave therapy (ESWT) for wound healing: technology, mechanisms, and clinical efficacy. Wound Repair Regen 2012;20:456–465
    1. Wang CJ, Wu RW, Yang YJ. Treatment of diabetic foot ulcers: a comparative study of extracorporeal shockwave therapy and hyperbaric oxygen therapy. Diabetes Res Clin Pract 2011;92:187–193
    1. Li VW, Kung EF, Li WW. Molecular therapy for wounds: modalities for stimulating angiogenesis and granulation. In: Yee BY, ed. The Wound Management Manual. New York, NY: McGraw Hill, 2005:17–43
    1. Knighton DR, Ciresi K, Fiegel VD, Schumerth S, Butler E, Cerra F. Stimulation of repair in chronic, nonhealing, cutaneous ulcers using platelet-derived wound healing formula. Surg Gynecol Obstet 1990;170:56–60
    1. Knighton DR, Ciresi KF, Fiegel VD, Austin LL, Butler EL. Classification and treatment of chronic nonhealing wounds. Successful treatment with autologous platelet-derived wound healing factors (PDWHF). Ann Surg 1986;204:322–330
    1. Knighton DR, Doucette M, Fiegel VD, Ciresi K, Butler E, Austin L. The use of platelet derived wound healing formula in human clinical trials. Prog Clin Biol Res 1988;266:319–329
    1. Steed DL, Goslen JB, Holloway GA, Malone JM, Bunt TJ, Webster MW. Randomized prospective double-blind trial in healing chronic diabetic foot ulcers. CT-102 activated platelet supernatant, topical versus placebo. Diabetes Care 1992;15:1598–1604
    1. Frykberg RG, Driver VR, Carman D, et al. . Chronic wounds treated with a physiologically relevant concentration of platelet-rich plasma gel: a prospective case series. Ostomy Wound Manage 2010;56:36–44
    1. Driver VR, Hanft J, Fylling CP, Beriou JM, Autologel Diabetic Foot Ulcer Study G. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. Ostomy Wound Manage 2006;52:68–70, 72, 74 passim
    1. Ramos-Torrecillas J, Luna-Bertos E, Garcia-Martinez O, Ruiz C. Clinical utility of growth factors and platelet-rich plasma in tissue regeneration: a review. Wounds 2014;26:2017–2213
    1. Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair Regen 1999;7:335–346
    1. Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group. J Vasc Surg 1995;21:71–78; discussion 79–81
    1. Wieman TJ. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group. Am J Surg 1998;176:74S–79S
    1. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care 1998;21:822–827
    1. Margolis DJ, Bartus C, Hoffstad O, Malay S, Berlin JA. Effectiveness of recombinant human platelet-derived growth factor for the treatment of diabetic neuropathic foot ulcers. Wound Repair Regen 2005;13:531–536
    1. Falanga V, Eaglstein WH, Bucalo B, Katz MH, Harris B, Carson P. Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers. J Dermatol Surg Oncol 1992;18:604–606
    1. Fernandez-Montequin JI, Infante-Cristia E, Valenzuela-Silva C, et al. . Intralesional injections of Citoprot-P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. Int Wound J 2007;4:333–343
    1. Fernandez-Montequin JI, Valenzuela-Silva CM, Diaz OG, et al. . Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study. Int Wound J 2009;6:432–443
    1. Gomez-Villa R, Aguilar-Rebolledo F, Lozano-Platonoff A, et al. . Efficacy of intralesional recombinant human epidermal growth factor in diabetic foot ulcers in Mexican patients: a randomized double-blinded controlled trial. Wound Repair Regen 2014;22:497–503
    1. Hong JP, Jung HD, Kim YW. Recombinant human epidermal growth factor (EGF) to enhance healing for diabetic foot ulcers. Ann Plast Surg 2006;56:394–398; discussion 399–400
    1. Mohan VK. Recombinant human epidermal growth factor (REGEN-D 150): effect on healing of diabetic foot ulcers. Diabetes Res Clin Pract 2007;78:405–411
    1. Singla S, Garg R, Kumar A, Gill C. Efficacy of topical application of beta urogastrone (recombinant human epidermal growth factor) in Wagner's Grade 1 and 2 diabetic foot ulcers: comparative analysis of 50 patients. J Nat Sci Biol Med 2014;5:273–277
    1. Valenzuela-Silva CM, Tuero-Iglesias AD, Garcia-Iglesias E, et al. . Granulation response and partial wound closure predict healing in clinical trials on advanced diabetes foot ulcers treated with recombinant human epidermal growth factor. Diabetes Care 2013;36:210–215
    1. Tsang MW, Wong WK, Hung CS, et al. . Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care 2003;26:1856–1861
    1. Morimoto N, Yoshimura K, Niimi M, et al. . Novel collagen/gelatin scaffold with sustained release of basic fibroblast growth factor: clinical trial for chronic skin ulcers. Tissue Eng Part A 2013;19:1931–1940
    1. O'Goshi K, Tagami H. Basic fibroblast growth factor treatment for various types of recalcitrant skin ulcers: reports of nine cases. J Dermatol Treat 2007;18:375–381
    1. Ohura T, Nakajo T, Moriguchi T, et al. . Clinical efficacy of basic fibroblast growth factor on pressure ulcers: case-control pairing study using a new evaluation method. Wound Repair Regen 2011;19:542–551
    1. Robson MC, Phillips TJ, Falanga V, et al. . Randomized trial of topically applied repifermin (recombinant human keratinocyte growth factor-2) to accelerate wound healing in venous ulcers. Wound Repair Regen 2001;9:347–352
    1. Yao C, Yao P, Wu H, Zha Z. Acceleration of wound healing in traumatic ulcers by absorbable collagen sponge containing recombinant basic fibroblast growth factor. Biomed Mater 2006;1:33–37
    1. Schultz GS, Davidson JM, Kirsner RS, Bornstein P, Herman IM. Dynamic reciprocity in the wound microenvironment. Wound Repair Regen 2011;19:134–148
    1. Schultz GS, Wysocki A. Interactions between extracellular matrix and growth factors in wound healing. Wound Repair Regen 2009;17:153–162
    1. Greaves NS, Iqbal SA, Baguneid M, Bayat A. The role of skin substitutes in the management of chronic cutaneous wounds. Wound Repair Regen 2013;21:194–210
    1. Badylak SF, Freytes DO, Gilbert TW. Extracellular matrix as a biological scaffold material: structure and function. Acta Biomater 2009;5:1–13
    1. Mulder G, Harding K, Kirsner R, Lee D, Serena T. International consensus. Acellular Matrices for the Treatment of Wounds. An expert working group review. London: Wounds International, 2010.
    1. Kimmel H, Rahn M, Gilbert TW. The clinical effectiveness in wound healing with extracellular matrix derived from porcine urinary bladder matrix: a case series on severe chronic wounds. J Am Col Certif Wound Spec 2010;2:55–59
    1. Lullove E. Acellular fetal bovine dermal matrix in the treatment of nonhealing wounds in patients with complex comorbidities. J Am Podiatr Med Assoc 2012;102:233–239
    1. Lun S, Irvine SM, Johnson KD, et al. . A functional extracellular matrix biomaterial derived from ovine forestomach. Biomaterials 2010;31:4517–4529
    1. Mitchell KB, Gallagher JJ. Porcine bladder extracellular matrix for closure of a large defect in a burn contracture release. J Wound Care 2012;21:454–456
    1. Negron L, Lun S, May BC. Ovine forestomach matrix biomaterial is a broad spectrum inhibitor of matrix metalloproteinases and neutrophil elastase. Int Wound J 2014;11:392–397
    1. Niezgoda JA, Van Gils CC, Frykberg RG, Hodde JP. Randomized clinical trial comparing OASIS wound matrix to regranex gel for diabetic ulcers. Adv Skin Wound Care 2005;18:258–266
    1. Kavros SJ, Dutra T, Gonzalez-Cruz R, et al. . The use of PriMatrix, a fetal bovine acellular dermal matrix, in healing chronic diabetic foot ulcers: a prospective multicenter study. Adv Skin Wound Care 2014;27:356–362
    1. Fleischli JG, Laughlin TJ, Fleischli JW. Equine pericardium collagen wound dressing in the treatment of the neuropathic diabetic foot wound: a pilot study. J Am Podiatr Med Assoc 2009;99:301–305
    1. Mostow EN, Haraway GD, Dalsing M, Hodde JP, King D; Group OVUS. Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: a randomized clinical trial. J Vasc Surg 2005;41:837–843
    1. Cervelli V, Lucarini L, Cerretani C, et al. . The use of Matriderm and autologous skin grafting in the treatment of diabetic ulcers: a case report. Int Wound J 2010;7:291–296
    1. Coban YK. Combination of negative pressure wound therapy and hyalomatrix application for soft tissue defect of the great toe. Int J Low Extrem Wounds 2012;11:155–156
    1. Gravante G, Delogu D, Giordan N, Morano G, Montone A, Esposito G. The use of Hyalomatrix PA in the treatment of deep partial-thickness burns. J Burn Care Res 2007;28:269–274
    1. Gravante G, Sorge R, Merone A, et al. . Hyalomatrix PA in burn care practice: results from a national retrospective survey, 2005 to 2006. Ann Plast Surg 2010;64:69–79
    1. Motolese A, Vignati F, Brambilla R, Cerati M, Passi A. Interaction between a regenerative matrix and wound bed in nonhealing ulcers: results with 16 cases. Biomed Res Int 2013;2013:849321.
    1. Clerici G, Caminiti M, Curci V, Quarantiello A, Faglia E. The use of a dermal substitute (integra) to preserve maximal foot length in a diabetic foot wound with bone and tendon exposure following urgent surgical debridement for an acute infection. Int J Low Extrem Wounds 2009;8:209–212
    1. Yao M, Attalla K, Ren Y, French MA, Driver VR. Ease of use, safety, and efficacy of integra bilayer wound matrix in the treatment of diabetic foot ulcers in an outpatient clinical setting: a prospective pilot study. J Am Podiatr Med Assoc 2013;103:274–280
    1. Reyzelman A, Crews RT, Moore JC, et al. . Clinical effectiveness of an acellular dermal regenerative tissue matrix compared to standard wound management in healing diabetic foot ulcers: a prospective, randomised, multicentre study. Int Wound J 2009;6:196–208
    1. Winters CL, Brigido SA, Liden BA, Simmons M, Hartman JF, Wright ML. A multicenter study involving the use of a human acellular dermal regenerative tissue matrix for the treatment of diabetic lower extremity wounds. Adv Skin Wound Care 2008;21:375–381
    1. Landsman AS, Cook J, Cook E, et al. . A retrospective clinical study of 188 consecutive patients to examine the effectiveness of a biologically active cryopreserved human skin allograft (TheraSkin(R)) on the treatment of diabetic foot ulcers and venous leg ulcers. Foot Ankle Spec 2011;4:29–41
    1. Sanders L, Landsman AS, Landsman A, et al. . A prospective, multicenter, randomized, controlled clinical trial comparing a bioengineered skin substitute to a human skin allograft. Ostomy Wound Manage 2014;60:26–38
    1. Greaves NS, Benatar B, Baguneid M, Bayat A. Single-stage application of a novel decellularized dermis for treatment-resistant lower limb ulcers: positive outcomes assessed by SIAscopy, laser perfusion, and 3D imaging, with sequential timed histological analysis. Wound Repair Regen 2013;21:813–822
    1. Yonehiro L, Burleson G, Sauer V. Use of a new acellular dermal matrix for treatment of nonhealing wounds in the lower extremities of patients with diabetes. Wounds 2013;25:340–344
    1. Iorio ML, Shuck J, Attinger CE. Wound healing in the upper and lower extremities: a systematic review on the use of acellular dermal matrices. Plast Reconstr Surg 2012;130:232S–241S
    1. Capito AE, Tholpady SS, Agrawal H, Drake DB, Katz AJ. Evaluation of host tissue integration, revascularization, and cellular infiltration within various dermal substrates. Ann Plast Surg 2012;68:495–500
    1. Litwiniuk M, Grzela T. Amniotic membrane: new concepts for an old dressing. Wound Repair Regen 2014;22:451–456
    1. Koob TJ, Lim JJ, Massee M, et al. . Angiogenic properties of dehydrated human amnion/chorion allografts: therapeutic potential for soft tissue repair and regeneration. Vasc Cell 2014;6:10.
    1. Koob TJ, Rennert R, Zabek N, et al. . Biological properties of dehydrated human amnion/chorion composite graft: implications for chronic wound healing. Int Wound J 2013;10:493–500
    1. Maan ZN, Rennert RC, Koob TJ, Januszyk M, Li WW, Gurtner GC. Cell recruitment by amnion chorion grafts promotes neovascularization. J Surg Res 2015;193:953–962
    1. Fetterolf DE, Snyder RJ. Scientific and clinical support for the use of dehydrated amniotic membrane in wound management. Wounds 2012;24:299–307
    1. Cooke M, Tan EK, Mandrycky C, He H, O'Connell J, Tseng SC. Comparison of cryopreserved amniotic membrane and umbilical cord tissue with dehydrated amniotic membrane/chorion tissue. J Wound Care 2014;23:465–474, 476
    1. Zelen CM, Poka A, Andrews J. Prospective, randomized, blinded, comparative study of injectable micronized dehydrated amniotic/chorionic membrane allograft for plantar fasciitis—a feasibility study. Foot Ankle Int 2013;34:1332–1339
    1. Werber B, Martin E. A prospective study of 20 foot and ankle wounds treated with cryopreserved amniotic membrane and fluid allograft. J Foot Ankle Surg 2013;52:615–621
    1. Forbes J, Fetterolf DE. Dehydrated amniotic membrane allografts for the treatment of chronic wounds: a case series. J Wound Care 2012;21:290, 292, 294–296
    1. Mermet I, Pottier N, Sainthillier JM, et al. . Use of amniotic membrane transplantation in the treatment of venous leg ulcers. Wound Repair Regen 2007;15:459–464
    1. Shah AP. Using amniotic membrane allografts in the treatment of neuropathic foot ulcers. J Am Podiatr Med Assoc 2014;104:198–202
    1. Zelen CM. An evaluation of dehydrated human amniotic membrane allografts in patients with DFUs. J Wound Care 2013;22:347–348, 350–341
    1. Zelen CM, Gould L, Serena TE, Carter MJ, Keller J, Li WW. A prospective, randomised, controlled, multi-centre comparative effectiveness study of healing using dehydrated human amnion/chorion membrane allograft, bioengineered skin substitute or standard of care for treatment of chronic lower extremity diabetic ulcers. Int Wound J 2014. [Epub ahead of print]; DOI: 10.1111/iwj.12395
    1. Zelen CM, Serena TE, Denoziere G, Fetterolf DE. A prospective randomised comparative parallel study of amniotic membrane wound graft in the management of diabetic foot ulcers. Int Wound J 2013;10:502–507
    1. Zelen CM, Serena TE, Snyder RJ. A prospective, randomised comparative study of weekly versus biweekly application of dehydrated human amnion/chorion membrane allograft in the management of diabetic foot ulcers. Int Wound J 2014;11:122–128
    1. Eaglstein WH, Falanga V. Tissue engineering and the development of Apligraf a human skin equivalent. Adv Wound Care 1998;11:1–8
    1. Falanga V, Margolis D, Alvarez O, et al. . Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Human Skin Equivalent Investigators Group. Arch Dermatol 1998;134:293–300
    1. Eaglstein WH, Iriondo M, Laszlo K. A composite skin substitute (graftskin) for surgical wounds. A clinical experience. Dermatol Surg 1995;21:839–843
    1. Veves A, Falanga V, Armstrong DG, Sabolinski ML; Apligraf Diabetic Foot Ulcer S. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 2001;24:290–295
    1. Edmonds M, European; Australian Apligraf Diabetic Foot Ulcer Study G. Apligraf in the treatment of neuropathic diabetic foot ulcers. Int J Low Extrem Wounds 2009;8:11–18
    1. Marston WA, Sabolinski ML, Parsons NB, Kirsner RS. Comparative effectiveness of a bilayered living cellular construct and a porcine collagen wound dressing in the treatment of venous leg ulcers. Wound Repair Regen 2014;22:334–340
    1. Mansbridge J, Liu K, Patch R, Symons K, Pinney E. Three-dimensional fibroblast culture implant for the treatment of diabetic foot ulcers: metabolic activity and therapeutic range. Tissue Eng 1998;4:403–414
    1. Roberts C, Mansbridge J. The scientific basis and differentiating features of Dermagraft. Can J Plast Surg 2002;10:6A–13A
    1. Naughton G, Mansbridge J, Gentzkow G. A metabolically active human dermal replacement for the treatment of diabetic foot ulcers. Artif Organs 1997;21:1203–1210
    1. Marston WA, Hanft J, Norwood P, Pollak R. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care 2003;26:1701–1705
    1. Harding K, Sumner M, Cardinal M. A prospective, multicentre, randomised controlled study of human fibroblast-derived dermal substitute (Dermagraft) in patients with venous leg ulcers. Int Wound J 2013;10:132–137
    1. Angirasa AK, Willrich A, Cooper B, Stuck R. Combining bioengineered human dermal replacement and multilayered compression dressings to manage ulcers in a person with diabetes mellitus: a case study. Ostomy Wound Manage 2006;52:60–64
    1. Frykberg R, Martin E, Tallis A, Tierney E. A case history of multimodal therapy in healing a complicated diabetic foot wound: negative pressure, dermal replacement and pulsed radio frequency energy therapies. Int Wound J 2011;8:132–139
    1. Kashefsky H, Marston W. Total contact casting combined with human fibroblast-derived dermal tissue in 15 DFU patients. J Wound Care 2012;21:236, 238, 240, 242–233
    1. Martin E, Tierney E, Tallis A, Frykberg RG. Use of human fibroblast derived dermal substitute (HFDDS) to close a complex chronic wound in the presence of peripheral arterial disease. J Diabet Foot Complications 2013;5:39–43
    1. Frykberg RG, Marston WA, Cardinal M. The incidence of lower-extremity amputation and bone resection in diabetic foot ulcer patients treated with a human fibroblast-derived dermal substitute. Adv Skin Wound Care 2015;28:17–20
    1. Caplan AI. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 2007;213:341–347
    1. Wu Y, Huang S, Enhe J, Fu X. Insights into bone marrow-derived mesenchymal stem cells safety for cutaneous repair and regeneration. Int Wound J 2012;9:586–594
    1. Maxson S, Lopez EA, Yoo D, Danilkovitch-Miagkova A, Leroux MA. Concise review: role of mesenchymal stem cells in wound repair. Stem Cells Transl Med 2012;1:142–149
    1. Bajada S, Mazakova I, Richardson JB, Ashammakhi N. Updates on stem cells and their applications in regenerative medicine. J Tissue Eng Reg Med 2008;2:169–183
    1. Wu Y, Wang J, Scott PG, Tredget EE. Bone marrow-derived stem cells in wound healing: a review. Wound Repair Regen 2007;15 Suppl 1:S18–S26
    1. Murray IR, Corselli M, Petrigliano FA, Soo C, Peault B. Recent insights into the identity of mesenchymal stem cells: implications for orthopaedic applications. Bone Joint J 2014;96-B:291–298
    1. Tseng SS, Lee MA, Reddi AH. Nonunions and the potential of stem cells in fracture-healing. J Bone Joint Surg Am 2008;90 Suppl 1:92–98
    1. Benoit E, O'Donnell TF, Patel AN. Safety and efficacy of autologous cell therapy in critical limb ischemia: a systematic review. Cell Transplant 2013;22:545–562
    1. Rogers LC, Bevilacqua NJ, Armstrong DG. The use of marrow-derived stem cells to accelerate healing in chronic wounds. Int Wound J 2008;5:20–25
    1. Wu Y, Chen L, Scott PG, Tredget EE. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells 2007;25:2648–2659
    1. Fioretti F, Lebreton-DeCoster C, Gueniche F, et al. . Human bone marrow-derived cells: an attractive source to populate dermal substitutes. Wound Repair Regen 2008;16:87–94
    1. Yamaguchi Y, Yoshida S, Sumikawa Y, et al. . Rapid healing of intractable diabetic foot ulcers with exposed bones following a novel therapy of exposing bone marrow cells and then grafting epidermal sheets. Br J Dermatol 2004;151:1019–1028
    1. Cha J, Falanga V. Stem cells in cutaneous wound healing. Clin Dermatol 2007;25:73–78
    1. Gu C, Huang S, Gao D, et al. . Angiogenic effect of mesenchymal stem cells as a therapeutic target for enhancing diabetic wound healing. Int J Low Extrem Wounds 2014;13:88–93
    1. Jiang XY, Lu DB, Chen B. Progress in stem cell therapy for the diabetic foot. Diabetes Res Clin Pract 2012;97:43–50
    1. Jain P, Perakath B, Jesudason MR, Nayak S. The effect of autologous bone marrow-derived cells on healing chronic lower extremity wounds: results of a randomized controlled study. Ostomy Wound Manage 2011;57:38–44
    1. Peng Y, Huang S, Cheng B, et al. . Mesenchymal stem cells: a revolution in therapeutic strategies of age-related diseases. Ageing Res Rev 2013;12:103–115
    1. Regulski M, Jacobstein DA, Petranto RD, Migliori VJ, Nair G, Pfeiffer D. A retrospective analysis of a human cellular repair matrix for the treatment of chronic wounds. Ostomy Wound Manage 2013;59:38–43
    1. Lavery LA, Fulmer J, Shebetka KA, et al. . The efficacy and safety of Grafix((R)) for the treatment of chronic diabetic foot ulcers: results of a multi-centre, controlled, randomised, blinded, clinical trial. Int Wound J 2014;11:554–560

Source: PubMed

3
Iratkozz fel